Sanofi (ENXTPA: SAN) is expected to report Q4 earnings on Feb. 7. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Sanofi's revenues will increase 2.4% and EPS will wane -23.2%.
The average estimate for revenue is $11.32 billion. On the bottom line, the average EPS estimate is $1.56.
Last quarter, Sanofi tallied revenue of $11.61 billion. GAAP reported sales were 3.8% lower than the prior-year quarter's $12.33 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $2.16. GAAP EPS of $1.52 for Q3 were 25% lower than the prior-year quarter's $2.04 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 68.8%, 40 basis points better than the prior-year quarter. Operating margin was 24.6%, 90 basis points better than the prior-year quarter. Net margin was 16.9%, 520 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $46.30 billion. The average EPS estimate is $8.09.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sanofi is outperform, with an average price target of $90.41.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Sanofi. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Sanofi to My Watchlist.